In CTCL, IL17F expression is driven via the IL2-JAK3-STAT5 pathway reportedly activated by a particular mutation of SOCS1 [69]. This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.